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Abstract
Hypoxia is involved in the development of chronic inflammatory processes. Under hypoxic
conditions HIF1A, VEGF and VEGFR2 are expressed and mediate the course of the resul-
tant disease. The aim of the present study was to define the associations between tSNPs in
these genes and COPD susceptibility and progression in a Spanish cohort. The T alleles in
rs3025020 and rs833070 SNPs (VEGFA gene) were less frequent in the group of COPD
cases and were associated with a lower risk of developing the disease (OR = 0.60; 95%
CI = 0. 39–0.93; p = 0.023 and OR = 0.60; 95% CI = 0.38–0.96; p = 0.034, respectively)
under a dominant model of inheritance. The haplotype in which both SNPs presented the T
allele confirmed the association found (OR = 0.02; 95% CI = 0.00 to 0.66; p = 0.03). More-
over, patients with COPD carrying the T allele in homozygosis in rs3025020 SNP showed
higher lung function values and this association remained constant during 3 years of follow-
up. In conclusion, T allele in rs833070 and rs3025020 may confer a protective effect to
COPD susceptibility in a Spanish population and the association of the SNP rs3025020
with lung function may be suggesting a role for VEGF in the progression of the disease.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death worldwide, mainly
caused by tobacco smoking. As pulmonary function deteriorates, and as the disease progresses,
the risk of alveolar hypoxia and consequent hypoxemia increase. The principal contributor to
hypoxemia in COPD patients is ventilation/perfusion (V/Q) mismatch resulting from progres-
sive airflow limitation and emphysematous destruction of the pulmonary capillary bed. It now
seems clear that tissue hypoxia is a key player in many of the processes and extrapulmonary
comorbidities that characterize COPD.
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The chronic hypoxemia could promote the expression of proteins that are involved in the
transport of oxygen (erythropoietin), in the vasculogenesis and angiogenesis (vascular endo-
thelial growth factor, VEGF and its receptors) or by the stimulation of expression of other
genes (hypoxia inducible factor -1, HIF-1). HIF-1 is a transcription factor that acts as principal
regulator of oxygen homeostasis, playing a fundamental role in the physiological response to
hypoxia. It is a heterodimer composed of two subunits: HIF-1α and HIF-1β. HIF-1β is a consti-
tutive core protein, whereas expression of HIF-1α is regulated by oxygen concentration. Fur-
thermore, there is evidence that hypoxia is involved in the development of chronic
inflammatory processes [1] and factor hypoxia-1 inducible acts as a regulator of the develop-
ment of inflammation [2,3]. In fact, HIF-1 can also be activated in response to several inflam-
matory stimuli [4,5]. Nevertheless, the possible involvement of genetic alterations in HIF1A
has not been previously studied in the COPD inflammation process caused by tobacco. VEGF
is one of the most important angiogenic factors. Its action depends on its interaction with spe-
cific receptors, mainly VEGFR2 (also known as KDR). These proteins are expressed in different
cell types and organs, being the alveoli and pulmonary epithelium the areas with higher expres-
sion in patients with COPD [6]. Under hypoxic conditions, VEGFA and VEGFR2 gene expres-
sion are regulated by the action of HIF-1, acting in its specific binding site in the promoter.
There are three genetic association studies that attempted to explore the relationship between
polymorphisms in the HIF1A and VEGFA genes and the risk of COPD in a Japanese [7] and
Chinese [8,9] populations, with negative results. However, Ding et al., found an haplotype in
VEGFA gene that could be associated with an increased risk of COPD in Chinese population
[9]. Furthermore, Sharma et al. [10] had described an association of SNPs in VEGFA gene with
FEV1/FVC when studied the progress of asthma in children and Simpson et al. [11] study in
population-based and asthma cohorts suggest an important role of VEGFA SNPs in airway
function at different ages.
The aim of the present study was to determine whether Single Nucleotide Polymorphisms
(SNPs) inHIF1A, VEGFA and VEGFR2 genes are associated with susceptibility and develop-
ment of COPD in a Spanish population.
Materials and Methods
Study population and clinical parameters
Participants in the study were divided into three groups: patients with COPD, smokers without
COPD and nonsmoking controls without respiratory disease (healthy controls).
Patients with COPD were recruited from the pulmonary clinic at the Hospital Universitario
Nuestra Señora de Candelaria from Tenerife (Spain) since 1997. Inclusion criteria were:35
years, smoking history of20 pack-year and FEV1/FVC ratio<0.7 measured 20 minutes after
administration of 400 mg of inhaled albuterol. In addition, patients were clinically stable for at
least 6 weeks prior to the evaluation of respiratory symptoms, lung function and sample collec-
tion. Individuals were excluded if they had history of other diseases like asthma or bronchiecta-
sis, and if they had physical or mental inability to perform different tests. The control group of
current smokers without COPD were selected, mostly in the pulmonary clinic at HUNSC and
a small proportion was obtained from an adult general population cohort (CDC), from the
Canary Islands [12] created to study the 3 most prevalent diseases in the Canary Islands: car-
diovascular disease, diabetes and cancer. The inclusion criteria for this control group were35
years, smoking history of 15 pack-year and normal lung function, defined as post bronchodi-
lator FEV1/FVC ratio 0.7 and absence of lung diseases. As a second control group, we
included healthy individuals without smoking history composed entirely by patients 35
years from the CDC study cited above.
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In order to minimize any possible effect of population structure on our estimations, cases
and control individuals were recruited if they have at least two generations of Canarian ances-
try [13].
This work had the approval of the Ethics Committee of Clinical Investigation of the Hospi-
tal Universitario Nuestra Señora de Candelaria (PI-10/08, PI-06/09) and the written inform
consent of all patients.
In terms of the clinical parameters, patients with COPD were interviewed once a year. At
each visit clinical variables were recorded as follows: nutritional assessment was performed
using the body mass index (BMI) calculated as the ratio of weight in kg and height in meters
squared. Pulmonary function tests were performed following American Thoracic Society
guidelines [14]. Diffusion capacity for carbon monoxide was determined with the single-breath
technique following the European Respiratory Society/American Thoracic Society guidelines
[15]. The arterial oxygen tension (PaO2) was measured at rest and dyspnea was assessed using
the modified MRC scale (mMRC) [16]. Exercise capacity was also tested using the best of two
6-min walking distance (6MWD) tests separated by at least 30 min following the ATS recom-
mendations [17]. The BODE (Body Mass Index, Airflow Obstruction, Dyspnea, Exercise Per-
formance) Index was calculated as previously described [18].
Genotyping and serummeasurements
TagSNPs in the candidate genes were identified using the Haploview program (v4.1) [19] and
data from Caucasian population available in SeattleSNP (http://pga.gs.whashington.edu/) and
HapMap (http://hapmap.ncbi.nlm.nih.gov/) databases. A multimarker tagging algorithm with
criteria of r2 cutoff for linkage disequilibrium clustering set to 0.8 and minor allele frequency
(MAF) 0.1 were used. Additionally, other polymorphisms were included in the study due to
its position in the gene or the relevant information provided in the scientific literature.
DNA was extracted from peripheral blood samples using commercial Illustra Blood Geno-
mic Prep Mini Spin Kit (GE Healthcare) according to the manufacturer's instructions. Geno-
typing was performed using iPlex-Gold (Sequenom) platform at the National Genotyping
Center (CeGen-ISCIII). Cases and controls were randomly placed on the plates, so that it was a
double-blind trial. Arrays with the results of the analysis were downloaded from the SNPator
platform [20]. A random 10% of samples were sequenced to confirm the results of genotyping
using an ABI Prism 310 Genetic Analyzer (Applied Biosystems).
Serum of COPD patients was separated from whole blood by centrifugation (3200 rpm) and
aliquots were stored at -80°C until laboratory analysis. TNF-α and VEGF levels in serum were
determined by noncompetitive enzyme-linked immunosorbent assay (ELISA), using different
available commercial kits (R&D Systems Inc.) following the manufacturer's instructions. The
within-assay coefficient of variation for all assays was less than 10%.
Replication study and statistical analysis
197 COPD patients and 192 smokers without COPD were kindly donated from Clínica Uni-
versitaria de Navarra, and 500 nonsmoking controls from National DNA Bank, and used for
genotyping by the iPlex-Gold platform. These individuals were selected following the same
inclusion and exclusion criteria previously described.
Statistical analysis was performed using SPSS (v.21) (IBM SPSS Statistics for Windows,
Armonk- IBM Corp.). ANOVA, Student t, Kruskal-Wallis, Mann-Whitney U and χ2 Pear-
son tests were used as appropriate. Multivariate logistic regression analysis was used to
adjust for independent predictors (age, gender, pack-years of smoking) in each case. General
linear model (GLM) for repeated measures was used to assess disease progression from
HIF1A, VEGFA and VEGFR2 SNPs in the Susceptibility and Progression of COPD
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longitudinal clinical and lung data. For genetic analysis, χ2 Pearson test was used for com-
parisons of allelic and genotypic distribution between patients with COPD and the two con-
trol groups. The values of linkage disequilibrium (LD) and Hardy-Weinberg were calculated
using GENEPOP v3.4 [21, 22] and Haploview (v4.1) [18]. The haplotype analysis was per-
formed using PHASE program (v2.1) [23]. To determine the associations and verify the con-
sistency of the inferred data, haplotypes were reconstructed from the best average goodness-
of-fit output of six runs with 1,000 permutations. A multivariate logistic regression analysis
was performed to estimate the odds ratio (OR) specific for each genotype, with a confidence
interval (CI) of 95%, in susceptibility to COPD, using the SNPStats software [24]. In order
to reduce potential bias generated by the use of multiple tests, we estimate the effective num-
ber of independent test in every case where significant differences existed between patients
and controls [25]. In all tests, bilateral contrast hypothesis was considered significant p-
value less than 0.05.
Results
The demographic and baseline characteristics of the groups are summarized in Table 1. 725
samples were successfully genotyped: 189 patients with COPD and 536 control subjects.
COPD patients (139 men and 50 women) were mainly in mild to moderate stage of the disease
(56% in GOLD stages I- II).
Table 1. Demographic characteristics of individuals included in the association study at baseline.
Variable COPD patients (n = 142) Smoking controls (n = 77) Nonsmoking controls (n = 459) p-value
Gender (% male) 74 50 63 <0.0001
Age (years)* 63 ± 10 48 ± 10 50 ± 9 <0.0001
Smoking history (pack-yrs)†* 64 ± 28 35 ± 14 0 <0.0001
FEV1 (L)* 1.50 ± 0.7 3 ± 0.7 __ NA
FEV1 (% pred)* 56 ± 20 101 ± 14 __ NA
FVC (%)* 86 ± 22 107 ± 15 __ NA
FEV1/FVC* 51 ± 12 78 ± 7 __ NA
PaO2 (mmHg)* 69.3 ± 13.5 __ __ NA
IC/TLC (%) 34 ± 12 __ __ NA
KCO 58 ± 7 __ __ NA
6MWD (m)* 489 ± 89 __ __ NA
BMI (Kg/m2) * 28 ± 6 __ __ NA
mMRC dysnea** 1 (0–2) __ __ NA
BODE index** 2 (0–3) __ __ NA
BODE index  2‡ 103 __ __ NA
BODE index > 2‡ 46 __ __ NA
GOLD index I-II‡ 106 __ __ NA
GOLD index III-IV‡ 83 __ __ NA
* Data are presented as mean ± SD.
** Data are presented as median (P25-75).
† Number of packs of cigarettes smoked per day x number of years smoking.
‡ Number of subjects in the two groups of GOLD and BODE index considered to analysis.
Median was used as cutoff in the BODE index. FEV1: forced expiratory volume in one second; FVC: forced expiratory volume; % pred: predicted
percentage; 6MWD: six-min walk distance test; BMI: body mass index; IC: inspiratory capacity, TLC: total lung capacity; PaO2: partial pressure of oxygen
in arterial blood: NA: Not Applicable.
doi:10.1371/journal.pone.0154998.t001
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21 tSNPs (7 inHIF1A, 11 in VEGFA and 3 in VEGFR2 genes) were analyzed. All SNPs were
in Hardy-Weinberg equilibrium except rs2071559 in VEGFR2 gene, which was then excluded
from further analysis.
The SNPs studied inHIF1A and VEGFR2 genes showed no significant differences in their
frequency distribution within individuals with COPD when compared to both control groups
(Tables 2 and 3).
In the VEGFA gene, we found that the T allele in rs3025020 and rs833070 polymorphisms
was more frequent in the nonsmoking control group when comparing to the group of patients
with COPD. The presence of this allele in both SNPs was associated with a lower risk of devel-
oping the disease (OR = 0.60; 95% CI = 0. 39–0.93; p = 0.023 for rs3025020 and OR = 0.60;
95% CI = 0.38–0.96; p = 0.034, for rs833070) under a dominant model of inheritance, and after
correcting for independent predictors (gender, age and pack-year) in a multivariate analysis
(Table 3). These results were not observed when comparing the group of patients with COPD
and the one of smokers without the disease. After correcting for multiple testing by using the
effective number of independent test (9.72), the association of rs3025020 and rs833070 with
susceptibility to COPD lost significance (adjusted values: p>0.05).
No differences in the frequency distribution of haplotypes inHIF1A and VEGFR2 genes
between cases and non-smoking controls (p>0.05) were observed (S1 and S2 Tables). How-
ever, when comparing the inferred VEGFA gene haplotypes in the group of cases versus
smoker controls, we found that the haplotype TTTATATCACG that appeared in our popula-
tion with a frequency of 1.24%, was associated with a diminished COPD susceptibility
(OR = 0.02; 95% CI = 0.00–0.66; p = 0.03) after correcting for age, gender and pack-year
(Table 4). This haplotype presented the less frequent alleles (T) of the SNPs rs833070 and
rs3025020, which were firstly associated with COPD in the independent SNPs analysis. A list
of inferred haplotypes of VEGFA gene are presented in the Supporting information section (S3
Table).
Table 2. Association ofHIF1A polymorphisms with COPD.
SNP Minor
Allele
COPD patients MAF
(%)
Nonsmoking MAF
(%)
Smoking controls
MAF (%)
ORaj (95%
CI)a
p-
value
ORaj (95%
CI)a
p-
value
rs2301106 C 0.14 0.14 0.10 1.23 (0.80–
1.89)
>0.05 1.86 (0.84–
4.12)
>0.05
rs12434438 G 0.33 0.32 0.27 1.16 (0.84–
1.59)
>0.05 1.29 (0.76–
2.16)
>0.05
rs11158358 G 0.21 0.21 0.18 1.20 (0.82–
1.76)
>0.05 1.30 (0.70–
2.41)
>0.05
rs10873142 C 0.32 0.28 0.24 1.27 (0.91–
1.77)
>0.05 1.44 (0.83–
2.49)
>0.05
rs41508050 T 0.01 0.01 0.00 0.66 (0.13–
3.39)
>0.05 NA (0.00-NA)* >0.05
rs2301113 C 0.37 0.33 0.29 1.20 (0.87–
1.64)
>0.05 1.29 (0.74–
2.33)
>0.05
rs4902080 T 0.07 0.08 0.09 0.93 (0.52–
1.66)
>0.05 0.65 (0.27–
1.55)
>0.05
a COPD patients vs. nonsmokers.
b COPD patients vs. smokers.
Data are presented as MAF: minor allele frequency; %: percentage; ORad: adjusted odds ratio; CI: confidence interval. Age, gender and pack-year were
included in a multivariate logistic regression analyses as potential independent predictors in an additive model.
* There is not enough individuals with TT genotype to complete the model.
doi:10.1371/journal.pone.0154998.t002
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Furthermore, COPD patients that carried the TT genotype of SNP rs3025020 presented
higher lung function values overtime. We found that the presence of the minor allele T in
homozygosis was significantly associated with a better lung function measured by FEV1 (%
pred). This association remained constant over time when performing a longitudinal analysis
of FEV1 during the 3-year follow-up period (p = 0.017) (Fig 1).
Table 3. Association of VEGFA and VEGFR2 polymorphisms with COPD.
SNP Minor
Allele
COPD patients
MAF (%)
Nonsmoking controls
MAF (%)
Smoking controls
MAF (%)
ORaj (95%
CI)a
p-
value
ORaj (95%
CI) b
p-
value
rs833069 C 0.41 0.38 0.41 1.09 (0.81–
1.47)
>0.05 1.04 (0.60–
1.80)
>0.05
rs833070 T 0.43 0.47 0.41 0.60 (0.38–
0.96)
0.034* 1.15 (0.67–
1.95)
>0.05
rs3025007 T 0.40 0.39 0.39 0.96 (0.70–
1.30)
>0.05 0.85 (0.50–
1.44)
>0.05
rs3025009 G 0.43 0.42 0.43 1.07 (0.79–
1.44)
>0.05 1.00 (0.58–
1.71)
>0.05
rs3025010 C 0.33 0.37 0.37 0.84 (0.60–
1.16)
>0.05 1.02 (0.58–
1.79)
>0.05
rs3025012 G 0.14 0.13 0.13 1.27 (0.83–
1.93)
>0.05 1.23 (0.60–
2.51)
>0.05
rs3025020 T 0.25 0.31 0.22 0.60 (0.39–
0.93)
0.023* 1.19 (0.61–
2.33)
>0.05
rs3025032 T 0.32 0.32 0.35 1.19 (0.86–
1.64)
>0.05 1.45 (0.80–
2.62)
>0.05
rs3025033 G 0.18 0.15 0.17 1.16 (0.78–
1.75)
>0.05 0.95 (0.49–
1.83)
>0.05
rs3025039 T 0.14 0.13 0.16 1.08 (0.69–
1.69)
>0.05 0.87 (0.41–
1.87)
>0.05
rs10434 A 0.42 0.43 0.43 1.09 (0.80–
1.48)
>0.05 1.35 (0.81–
2.27)
>0.05
rs1870377 A 0.20 0.19 0.24 1.17 (0.79–
1.73)
>0.05 0.96 (0.51–
1.81)
>0.05
rs2305948 T 0.12 0.12 0.11 1.08 (0.68–
1.73)
>0.05 0.95 (0.41–
2.16)
>0.05
a COPD patients vs. nonsmokers.
b COPD patients vs. smokers.
Data are presented as MAF: minor allele frequency; %: percentage; ORad: adjusted odds ratio; CI: confidence interval. Age, gender and pack-year were
included in a multivariate logistic regression analyses as potential independent predictors in an additive model.
*p<0.05 under a dominant model of inheritance.
doi:10.1371/journal.pone.0154998.t003
Table 4. VEGFA haplotype association with COPD susceptibility.
COPD patients vs. nonsmoking controls COPD patients vs. smoking controls
Haplotypea Frequency (%) ORaj (95%CI) p-value Frequency (%) ORaj (95%CI) p-value
CCCGTACTACA 13.78 1 __ 16.27 1 __
TTTATATCACG 0.80 NA (NA-NA) >0.05 1.24 0.02 (0.00–0.66) 0.03*
a rs833069/ rs833070/ rs3025007/ rs3025009/ rs3025010/ rs3025012/ rs3025020/ rs3025032/ rs3025033/ r3025039/ rs10434.
Data are presented as: %: percentage; ORaj: adjusted odds ratio; CI; confidence interval; NA: not analyzed (due to one allele has a frequency = 0.00).
Age, gender and pack-year were included in a multivariate logistic regression analyses as potential independent predictors in an additive model.
* p-value<0.05.
doi:10.1371/journal.pone.0154998.t004
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By studying hypoxia responsive genes, we decided to subdivide the sample of patients with
COPD according to their degree of hypoxemia (PaO2<60mmHg, severe hypoxemia). We did
not find any significant association between the analyzed SNPs and lung function variables
within the groups of moderate and severe hypoxemia (p> 0.05).
None of theHIF1A, VEGFA or VEGFR2 gene variants or haplotypes correlated with the
serum inflammatory markers levels (p> 0.05).
Regarding to the replication study in another Spanish cohort, of the studied SNPs and hap-
lotypes (S4 and S5 Tables), their distribution did not differ between the cases and controls
groups (p> 0.05).
Discussion
Our study explores the relationship between SNPs in the genesHIF1A, VEGFA and VEGFR2
with COPD. Our major finding is that we found not only an association of an haplotype con-
taining SNPs rs3025020 and rs833070 in the VEGFA gene with the susceptibility to disease, but
also an association of SNP rs3025020 with the progression of COPD.
Specifically, the T alleles in both polymorphisms in the VEGFA gene were present with a
higher frequency in the nonsmoking control group when compared to the patients with the
disease group. This finding was supported by the fact that the haplotype, in which both SNPs
present the T allele, was associated to a diminished COPD susceptibility. This is important
because haplotypes are capable of detecting differences when individual SNPs lost significance
due to small sample size. Furthermore, the presence of the TT genotype in rs3025020 seemed
to be associated with a better lung function, given by higher levels of FEV1 (% pred) when com-
pared to patients carrying the CT and CC genotypes. Interestingly, these differences were
observed along the longitudinal 3-years follow up period. Previously, different SNPs were asso-
ciated with lung function in population-based and asthma cohorts along time, suggesting a role
of VEGFA variants in lung function [10, 11] and one of them, rs3025028, was also associated
with the ratio of the active and inhibitory isoforms of VEGF-A165. Moreover, Ding et al. [9],
described an haplotype of VEGFA gene potentially associated with an increased COPD risk in
Fig 1. Lung function differences between rs3025020 genotypes in patients with Chronic Obstructive
Pulmonary Disease over time. FEV1 (% pred) for the three genotypes of SNP rs3025020 (VEGFA gene)
over time. The presence of allele T in homozygosis determined higher values of FEV1 (% pred) respect to the
other genotypes. The differences remained constant for every visit (** p-value<0.01; *** p-value<0.001) and
along 3 years of follow-up (p = 0.017). The sample size for each moment was: Baseline: N = 132; 1st year:
N = 118; 2nd year: N = 98 and 3rd year: N = 87.
doi:10.1371/journal.pone.0154998.g001
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an Asian population. However, to our knowledge this is the first study reporting the longitudi-
nal relationship between SNPs in VEGFA gene and disease progression in a well-characterized
cohort of patients with COPD.
Several studies deepen the association of rs3025020 in VEGFA gene with VEGF secretion,
with conflicting results. Ruggiero et al.,observed that TT genotype could increase serum levels
of VEGF in three Caucasian populations [26]. However, this study shows heterogeneity of
results depending on the population studied: polymorphisms associated with serum VEGF lev-
els in a population, not replicated this association in other populations analyzed. Al-Habboubi
et al. [27] find and association of T allele with higher serum levels of the protein in a healthy
cohort. However, they could not find this association in a posterior study of vasoocclusive crisis
in sickle cell disease [28]. According these results, we did not find association between VEGF
serum levels and the studied SNPs within the group of patients with the disease. Furthermore,
Boeck et al. (2015) [29] found that serum levels of VEGF measure at baseline, at stable and
exacerbated patients with COPD, were not associated with clinically significant outcomes, but
the VEGF course seems related to COPD prognosis. They observed that increased levels in
VEGF over time were associated with the exacerbation frequency, the 1- and 2-year hospitali-
zation rate as well as survival. Interestingly, Almawy et al. [30], suggest that the regulation of
VEGF serum levels is not only dependent of genetic factors, but also depend on local and sys-
temic factors accompanying the disease, which could explain our results.
Regarding the other studied SNPs, VEGFA polymorphism rs3025039 was previously studied
in relation to COPD in a Japanese population, but without positive results [7]. According to
this report, in our study we also analyzed the rs3025033 polymorphism, which is in linkage dis-
equilibrium with rs3025039, and found no significant associations with disease susceptibility.
Ding et al., also studied several SNPs of VEGFA gene, three of them included in our study
(rs833070, rs3025033 and rs10434) in Chinese population, with negative results [9]. Interest-
ingly, the difference between our results for SNP rs833070 and theirs could be due to differ-
ences in the genetic background of the studied populations.
To our knowledge, this is the first study that evaluated the association between VEGFR2
gene variants and COPD, without any significant result. Similarly, Ding et al. carried on a
study of HIF1A in Chinese population, but they also did not find significant differences for the
studied SNPs between patients and control groups [8]. Moreover, we did not find any relation-
ship between any variant of HIF1A and VEGFR2 genes and clinical or lung function parame-
ters in our COPD cohort in a cross sectional analysis.
This study has some limitations: firstly, a large sample size may be necessary principally in
the case of smokers without the disease to discard a type II error. Secondly, VEGF serum levels
were not measure in a control group to compare with the COPD patients group. Moreover, we
cannot rule out that the VEGF serum levels of the patients observed may be influenced by the
received treatment given to patients (such as inhaled corticosteroids) or by comorbidities.
Finally, in our cohort, in order to reduce the possibility of population stratification individuals
having at least two generations of canary ancestors were included. Along this line, we could not
found significant association between the studied gene variants and susceptibility to disease in
another cohort from Spain. The Canarian population has a particular genetic background, with
African influence [31] which may hamper the replication of the results in a similar cohort.
Nevertheless, this do not invalidate our previous findings.
In summary, this is the first study to assess the influence ofHIF1A and VEGFA gene vari-
ants in the susceptibility and progression of COPD in a Spanish population. Based on a well-
characterized cohort of patients with longitudinal follow-up the SNPs rs3025020 and rs833070
in the VEGFA gene were found associated with a lower risk susceptibility to the disease. In
addition, the patients with COPD who presented the rs3025020 TT genotype had a better
HIF1A, VEGFA and VEGFR2 SNPs in the Susceptibility and Progression of COPD
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preservation of lung function for a long monitoring period suggesting a role for VEGF in the
progression of COPD.
Supporting Information
S1 Table. Association study ofHIF1A haplotypes and COPD. a rs2301106/ rs12434438/
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